Gyre Therapeutics Inc. Common Stock

Documents

Financial318 concepts · 1,898 facts · Mar 2024 to Jun 2026

• Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Mar 2024 to Jun 2026
• Net income loss12 · Mar 2024 to Jun 2026
• Other comprehensive income loss foreign currency transaction and translation adjustment net of tax12 · Mar 2024 to Jun 2026
• Stockholders equity including portion attributable to noncontrolling interest12 · Mar 2024 to Jun 2026
• Stock issued during period value stock options exercised12 · Mar 2024 to Jun 2026
• Allocated share based compensation expense11 · Jun 2024 to Jun 2026
• Amortization of intangible assets11 · Jun 2024 to Jun 2026
• Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations11 · Jun 2024 to Jun 2026
• Comprehensive income net of tax11 · Jun 2024 to Jun 2026
• Comprehensive income net of tax attributable to noncontrolling interest11 · Jun 2024 to Jun 2026
• Cost of goods and services sold (US GAAP)11 · Jun 2024 to Jun 2026
• Costs and expenses11 · Jun 2024 to Jun 2026
• Fair value adjustment of warrants11 · Jun 2024 to Jun 2026
• General and administrative expense (US GAAP)11 · Jun 2024 to Jun 2026
• Income tax expense benefit11 · Jun 2024 to Jun 2026
• Net income loss attributable to noncontrolling interest11 · Jun 2024 to Jun 2026
• Net income loss available to common stockholders basic11 · Jun 2024 to Jun 2026
• Net income loss available to common stockholders diluted11 · Jun 2024 to Jun 2026
• Operating expenses (US GAAP)11 · Jun 2024 to Jun 2026
• Operating income loss11 · Jun 2024 to Jun 2026
• Operating lease expense11 · Jun 2024 to Jun 2026
• Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to noncontrolling interest11 · Jun 2024 to Jun 2026
• Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent11 · Jun 2024 to Jun 2026
• Other nonoperating income expense11 · Jun 2024 to Jun 2026

Segment22 concepts · 331 facts · Jun 2024 to Jun 2026

• Operating expenses (US GAAP)32 · Jun 2024 to Jun 2026
• General and administrative expense (US GAAP)30 · Jun 2024 to Mar 2026
• Operating income loss30 · Jun 2024 to Mar 2026
• Other nonoperating income expense25 · Jun 2024 to Jun 2026
• Income loss from continuing operations including portion attributable to noncontrolling interest24 · Jun 2024 to Mar 2026
• Research and development expense excluding acquired in process cost22 · Jun 2024 to Mar 2026
• Income tax expense benefit21 · Jun 2024 to Jun 2026
• Segment expenditure addition to long lived assets21 · Sep 2024 to Jun 2026
• Allocated share based compensation expense20 · Jun 2024 to Jun 2026
• Cost of goods and services sold (US GAAP)17 · Jun 2024 to Jun 2026
• Fair value adjustment of warrants17 · Jun 2024 to Jun 2026
• Revenue17 · Jun 2024 to Jun 2026
• Selling and marketing expense (US GAAP)17 · Jun 2024 to Jun 2026
• Interest income expense net9 · Dec 2024 to Jun 2026
• Transaction costs5 · Mar 2026 to Jun 2026
• Gain loss on disposition of assets14 · Jun 2024 to Sep 2025
• Gross profit (US GAAP)4 · Jun 2024 to Sep 2025
• (Loss) income from operations4 · Jun 2025 to Jun 2026
• Net segment (loss) income4 · Jun 2025 to Jun 2026
• Selling general and administrative expense4 · Jun 2025 to Jun 2026
• Gain loss on sale of property plant equipment2 · Dec 2024 to Dec 2025
• Research and development expense2 · Jun 2025

Product1 concepts · 8 facts · Jun 2024 to Jun 2026

• Revenue8 · Jun 2024 to Jun 2026

Statement business segments3 members · 331 facts

• Gyre Pharmaceuticals148 · Jun 2024 to Jun 2026
• Gyre122 · Jun 2024 to Jun 2026
• All Other Segments61 · Jun 2024 to Jun 2026

Product or service2 members · 8 facts

• Product6 · Jun 2024 to Mar 2026
• Pharmaceutical Products2 · Jun 2025 to Jun 2026